L A Emens

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Cancer vaccines in combination with multimodality therapy
    Leisha A Emens
    The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231 1000, USA
    Cancer Treat Res 123:227-45. 2005
  2. ncbi request reprint GM-CSF-secreting vaccines for solid tumors
    Leisha A Emens
    The Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Curr Opin Investig Drugs 10:1315-24. 2009
  3. pmc Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Expert Rev Anticancer Ther 12:1597-611. 2012
  4. pmc Re-purposing cancer therapeutics for breast cancer immunotherapy
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Cancer Immunol Immunother 61:1299-305. 2012
  5. pmc Toward integrative cancer immunotherapy: targeting the tumor microenvironment
    Leisha A Emens
    Tumor Immunology and Breast Cancer Research Programs, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Transl Med 10:70. 2012
  6. ncbi request reprint Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
    L A Emens
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000, USA
    Endocr Relat Cancer 12:1-17. 2005
  7. ncbi request reprint Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer
    Leisha A Emens
    Tumor Immunology and Breast Cancer Research Programs, Sidney Kimmel Comprehensive Cancer Center, Baltimore 21231 1000, Maryland, USA
    Am J Ther 12:243-53. 2005
  8. ncbi request reprint Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
    Leisha A Emens
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 65:8059-64. 2005
  9. ncbi request reprint Towards a therapeutic breast cancer vaccine: the next steps
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, MD 21231 1000, USA
    Expert Rev Vaccines 4:831-41. 2005
  10. ncbi request reprint Roadmap to a better therapeutic tumor vaccine
    Leisha A Emens
    Department of Oncology, Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Int Rev Immunol 25:415-43. 2006

Research Grants

  1. CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENT
    Leisha Emens; Fiscal Year: 2006

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Cancer vaccines in combination with multimodality therapy
    Leisha A Emens
    The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231 1000, USA
    Cancer Treat Res 123:227-45. 2005
  2. ncbi request reprint GM-CSF-secreting vaccines for solid tumors
    Leisha A Emens
    The Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Curr Opin Investig Drugs 10:1315-24. 2009
    ....
  3. pmc Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Expert Rev Anticancer Ther 12:1597-611. 2012
    ..Integrative breast cancer immunotherapies that strategically combine established breast cancer therapies with breast cancer vaccines, immune checkpoint blockade or both should result in durable clinical responses and increased cures...
  4. pmc Re-purposing cancer therapeutics for breast cancer immunotherapy
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Cancer Immunol Immunother 61:1299-305. 2012
    ....
  5. pmc Toward integrative cancer immunotherapy: targeting the tumor microenvironment
    Leisha A Emens
    Tumor Immunology and Breast Cancer Research Programs, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Transl Med 10:70. 2012
    ....
  6. ncbi request reprint Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
    L A Emens
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000, USA
    Endocr Relat Cancer 12:1-17. 2005
    ....
  7. ncbi request reprint Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer
    Leisha A Emens
    Tumor Immunology and Breast Cancer Research Programs, Sidney Kimmel Comprehensive Cancer Center, Baltimore 21231 1000, Maryland, USA
    Am J Ther 12:243-53. 2005
    ..This review summarizes the available clinical data on the use of trastuzumab in HER-neu-overexpressing breast cancer and briefly highlights emerging opportunities for innovative, trastuzumab-based breast cancer therapies...
  8. ncbi request reprint Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
    Leisha A Emens
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 65:8059-64. 2005
    ....
  9. ncbi request reprint Towards a therapeutic breast cancer vaccine: the next steps
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, MD 21231 1000, USA
    Expert Rev Vaccines 4:831-41. 2005
    ....
  10. ncbi request reprint Roadmap to a better therapeutic tumor vaccine
    Leisha A Emens
    Department of Oncology, Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Int Rev Immunol 25:415-43. 2006
    ..The first of these combinatorial trials have already been reported and offer a tantalizing glimpse of the future of cancer immunotherapy...
  11. pmc Chemotherapy and tumor immunity: an unexpected collaboration
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, Room 4M90, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Front Biosci 13:249-57. 2008
    ..Chemotherapy can be used with tumor vaccines in unexpected ways, breaking down these barriers and unleashing the full potential of the antitumor immune response...
  12. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  13. pmc Chemoimmunotherapy
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University, 1650 Orleans St, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Cancer J 16:295-303. 2010
    ....
  14. ncbi request reprint Augmenting the potency of breast cancer vaccines: combined modality immunotherapy
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Breast Dis 20:13-24. 2004
    ..Combined modality immunotherapies should maximize the potency of the antitumor immune response, thereby improving the outcome of breast cancer therapy...
  15. ncbi request reprint Survivin' cancer
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000, USA
    Cancer Biol Ther 3:180-3. 2004
  16. ncbi request reprint A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer
    Leisha A Emens
    Johns Hopkins Oncology Center, Baltimore, MD, USA
    Breast Cancer Res Treat 76:145-56. 2002
    ..Our aims were to determine the maximum tolerated dose (MTD) of 5-FU in the dose-dense regimen and to determine the impact of dose-dense chemotherapy on HDC/PBSCT...
  17. ncbi request reprint A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 2410, USA
    Hum Gene Ther 15:313-37. 2004
  18. ncbi request reprint Toward a breast cancer vaccine: work in progress
    Leisha A Emens
    Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Oncology (Williston Park) 17:1200-11; discussion 1214, 1217-8. 2003
    ....
  19. pmc Cancer vaccines: on the threshold of success
    Leisha A Emens
    Johns Hopkins University, Tumor Immunology and Breast Cancer Research Programs, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Expert Opin Emerg Drugs 13:295-308. 2008
    ..Additional advantages of cancer vaccines are exquisite specificity, low toxicity, and the potential for a durable treatment effect due to immunologic memory...
  20. ncbi request reprint Cancer vaccines: an old idea comes of age
    Leisha A Emens
    Departments of Oncology, The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland 21231 1000, USA
    Cancer Biol Ther 2:S161-8. 2003
    ....
  21. ncbi request reprint A new twist on autologous cancer vaccines
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000 USA
    Cancer Biol Ther 2:161-3. 2003
  22. ncbi request reprint To live or not to live: that depends on GAGE?
    Leisha A Emens
    Departments of Oncology, The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Cancer Biol Ther 1:388-90. 2002
  23. ncbi request reprint The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
    R T Reilly
    Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 61:880-3. 2001
    ..These data suggest that vaccines optimized to induce maximal T- and B-cell immunity to neu, and possibly to similar putative tumor-rejection antigens, may lead to more potent in vivo antitumor immunity...
  24. ncbi request reprint Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
    J P Machiels
    The Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Immunology, Baltimore, Maryland 21231, USA
    Cancer Res 61:3689-97. 2001
    ..These data provide the immunological rationale for testing immune-modulating doses of chemotherapy in combination with tumor vaccines in patients with cancer...
  25. ncbi request reprint Chemotherapy: friend or foe to cancer vaccines?
    L A Emens
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 3:77-84. 2001
    ..These interactions will require thorough preclinical evaluation to maximize the clinical impact of this type of therapeutic cancer vaccine...
  26. pmc Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
    Lukas W Pfannenstiel
    Department of Oncology, Sidney Kimmel Cancer Center, Division of Immunology, Johns Hopkins University, USA
    Cell Immunol 263:79-87. 2010
    ..Finally, PTX treatment results in enhanced antigen-specific, IFN-gamma-secreting CD8(+) T cells in vivo. Thus, administration of PTX with a tumor vaccine improves T cell priming through enhanced maturation of DC...
  27. ncbi request reprint Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?
    R T Reilly
    Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Curr Opin Investig Drugs 2:133-5. 2001
    ..This article seeks to explore the notion that a vaccine designed to optimally activate both arms of the immune system may well generate an antitumor immune response greater than the sum of the two individual effector mechanisms alone...
  28. ncbi request reprint HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
    Matthew E Wolpoe
    Department of Otolaryngology Head and Neck Surgery, Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Immunol 171:2161-9. 2003
    ..Collectively, these observations suggest that similarly increased efficacy could be obtained by combining neu-targeted vaccination and neu-specific Abs such as trastuzumab (Herceptin) in patients with neu-expressing cancers...
  29. ncbi request reprint A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
    Elizabeth A Manning
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 13:3951-9. 2007
    ....
  30. pmc Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
    Anne M Ercolini
    Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1591-602. 2005
    ....
  31. doi request reprint Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer
    Saranya Chumsri
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21231, USA
    Clin Breast Cancer 10:40-5. 2010
    ..We evaluated pathologic complete response (pCR) rate and cardiac safety of preoperative doxorubicin and cyclophosphamide followed by a taxane with or without trastuzumab...
  32. pmc Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs
    Peter S Kim
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
    J Clin Invest 118:1700-11. 2008
    ..This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment...
  33. ncbi request reprint Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility
    J M Davis-Sproul
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cytotherapy 7:46-56. 2005
    ..The aim of these studies was to optimize expansion parameters, qualify the manufacturing process, and establish expected outcomes for cGMP-compliant manufacturing of two GM-CSF-secreting breast tumor cell lines...
  34. ncbi request reprint Trastuzumab in breast cancer
    Leisha A Emens
    Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine Baltimore, Maryland 21231 1000, USA
    Oncology (Williston Park) 18:1117-28; discussion 1131-2, 1137-8. 2004
    ..Here we review the clinical development of this novel agent, emphasizing the potential for therapeutic synergy when trastuzumab is combined with both standard chemotherapy and innovative molecularly targeted and biologic agents...
  35. doi request reprint Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
    Richard C Zellars
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 27:2816-22. 2009
    ..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)...
  36. ncbi request reprint OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen
    Satoshi Murata
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 176:974-83. 2006
    ..These studies highlight the increased efficacy of OX40 costimulation when combined with a GM-CSF-secreting vaccine, and define a new role for OX40 costimulation of CD8+ T cells in overcoming tolerance and boosting antitumor immunity...
  37. pmc GM-CSF-secreting vaccines for solid tumors: moving forward
    Richa Gupta
    Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Discov Med 10:52-60. 2010
    ....
  38. ncbi request reprint Cytokine gene-modified cell-based cancer vaccines
    R Todd Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 69:233-57. 2002
  39. ncbi request reprint Adjuvant hormonal therapy for premenopausal women with breast cancer
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:486S-94S. 2003
    ....
  40. ncbi request reprint The follow-up of breast cancer
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA
    Semin Oncol 30:338-48. 2003
    ..Finally, we present an evidence-based approach to breast cancer surveillance after therapy that is consistent with several clinical practice guidelines, maximizing outcome and minimizing cost...
  41. ncbi request reprint GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers
    Pilar Nava-Parada
    The Johns Hopkins University and the Sidney Kimmel, Comprehensive Cancer Center Department of Oncology, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Curr Opin Mol Ther 9:490-7. 2007
    ..GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer...
  42. ncbi request reprint Cancer vaccines: toward the next revolution in cancer therapy
    Leisha A Emens
    Int Rev Immunol 25:259-68. 2006

Research Grants1

  1. CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENT
    Leisha Emens; Fiscal Year: 2006
    ..abstract_text> ..